Evidence based review on levosalbutamol

Indian Journal of Pediatrics

Volumn 74, Issue 2, 2007, Pages 161-167

  Gupta, Mukesh Kumar ^a   Singh, Meenu ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Asthma; Levosalbutamol or levalbuterol; Salbutamol

Indexed keywords

LEVALBUTEROL; PLACEBO; SALBUTAMOL; BETA ADRENERGIC RECEPTOR STIMULATING AGENT;

ARTICLE; ASTHMA; CLINICAL STUDY; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DRUG FORMULATION; EVIDENCE BASED PRACTICE; HUMAN; ISOMER; MARKET; NONHUMAN; PATIENT SATISFACTION; QUALITY OF LIFE; ADOLESCENT; ANIMAL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEVELOPING COUNTRY; DOSE RESPONSE; DRUG ADMINISTRATION; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HOSPITALIZATION; INDIA; INFANT; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; MALE; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENERGIC BETA-AGONISTS; ALBUTEROL; ANIMALS; ASTHMA; CHILD; CHILD, PRESCHOOL; DEVELOPING COUNTRIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDIA; INFANT; MALE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33947721536     PISSN: 00195456     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12098-007-0010-5     Document Type: Article

References (35)

1. Clive P, Jhon M. Contrasting properties of Albuterol stereoisomers. J Allergy Clin Immuno 1999; 104: S31-41.
2. Penn RB, Friele T, McCullough JR, Aberg G, Benovie JL. Comparision of R-, S-, RS-albuterol, interaction with human β2 adrenergic receptors. Clin Rev Allergy Immunol 1996; 14: 37-45.
3. Canning B. Pharmacological properties of S-albuterol in human airway smooth muscle preparations. Am J Resp Crit Care Med 2002; 165: A770.
4. Van Essen-Zandvliet EE, Hughes MD et al. Effects of 22 months of treatment with inhaled salbutamol lung function, airway responsiveness, and symptom in children with asthma. Am Rev Resp Dis 1992; 146: 547-554.
5. Waheda I, Wong CS, Wisniewski Afz et al. Asthma control during and after cessation of regular β2 agonist treatment. Am Rev Resp Dis 1993; 148: 707-712.
6. Taylor DR, Sears MR. Bronchodilators and bronchial hyperresponsiveness. Thorax 1994; 49(2): 190-191.
7. Mazzoni L, Naef R, Chapman ID, Morley J. Hyperresponsiveness of the airways to histamine following exposure of guinea pigs to racemic mixtures and distomers of β2-selective sympathomimetics. Pulm Pharmacol 1994; 7: 367-376.
8. Keir S, Page C, Spina D. Bronchial hyper-responsiveness induced by chronic treatment with albuterol: role of sensory nerves. J Allergy Clin Immunol 2002; 110: 388-394.
9. Templeton AGB, Chapman ID, Chilvers E, Morley J, Handley DA. Effects of (S)-albuterol on isolated human bronchus. Pulm Pharmacol 1998; 11: 1-6.
10. Mazzoni L, Naef R, Chapman ID, Morley J. Hyperresponsiveness of the airways to histamine following exposure of guinea pigs to racemic mixtures and distomers of β2-selective sympathomimetics. Pulm Pharmacol 1994; 7: 367-376.
11. Cockcroft DW, Swystun VA. Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine. Thorax 1997; 52: 845-848.
12. Ramsay CM, Cowan J, Flannery E, McLachlan C, Taylor DR. Bronchoprotective and bronchodilator effects of single doses of (S)-salbutamol, (R)-salbutamol and racemic salbutamol in patients with bronchial asthma. Eur J Clin Pharmacol 1999; 55: 353-359.
13. 2 agonist isomers, has stimulatory effects on mucin secretion and changes in gene expression on airway epithelium. Am J Resp Crit Care Med 2001; 161:A 144.
14. Perterson BT, Miller EJ, Effect of enatiomers of albuterol on lung epithelial permeability. Am J Resp Crit Care Med 2000; 161: A 416.
15. O'sullivan S, Cormican L, Faul JL, Ichinohe S, Johnston SL et al. Activated, cytotoxic CD8 + T lymphocytes contribute to the pathology of asthma death. Am J Resp Crit Care Med 2001; 164: 560-564.
16. 2 adrenergic agonists on eosinophil response to IL-5. J Allergy Clin Immunolo 1998; 111: S35.
17. Cho SH, Haartleroad JY, Oh CK. S-albuterol increases the production of histamine and IL-4 in mast cells. Int Arch Allergy Imunolo 2001; 124: 478-484.
18. 2 agonist enantiomers of salbutamol. J Allergy Clin Immunolo 2000; 105: S 292-293.
19. Kwong CC, Chung QN, Choi SS et al. Effects of isomers of albuterol, R-albuterol, and S-albuterol, on human granulocytic function. J Invest Med 2002; 50: 72 A.
20. Walle T, Walle UK, Thornburg KR, Schey KL. Stereoselective sulfation of albuterol in humans. Drug Meabo Dispos 1993; 21: 76-80.
21. Boulton DW, Fawcett JP. Enantioselective disposition of salbutamol in man following oral and inhaled administration. J Clin Pharmacol 1996; 41: 35-40.
22. Schmekel B, Rydberg I, Norlandar B, Sjosward KN. Stereoselective pharmacokinetics of S-salbutamol after administration of the racemate in healthy volunteers. Eur Respir J 1999; 13: 1230-1235.
23. Maier G, Henry A, Baumbgartner R et al. The effects of (S)-albuterol, is not through the alteration of the pharmacokinetics of (R)-albuterol: a population PK analysis. J Allergy Clin Immunol 2002; 109: S 237-239.
24. Nelson HS, Bensch G, Pleskow WW, DiSantostefano R, DeGraw S, Reasner DS, Rollins TE, Rubin PD. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol 1998; 102: 943-952.
25. Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol 1999; 103(4): 615-621.
26. Milgrom H, Skoner DP, Bensch G, Kim KT, Claus R, Baumgartner RA for the Levalbuterol Pediatric Study Group. Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. J Allergy Clin Immunol 2001; 108: 938-945.
27. Skoner DP, Greos LS, Kim KT, Roach JM, Parsey M, Baumgartner RA. Evaluation of the safety and efficacy of levalbuterol in 2-5-year-old patients with asthma. Pediatr Pulmonol 2005; 40: 477-486.
28. Lotvall J, Palmqvist M, Arvidsson P, Maloney A, Ventresca GP, Ward J. The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J Allergy Clin Immunol 2001; 108: 726-731.
29. Handley DA, Tinkelman D, Noonan M, Rollins TE, Snider ME, Caron J. Dose-response evaluation of levalbuterol versus racemic albuterol in patients with asthma. J Asthma 2000; 37: 319-327.
30. Carl JC, Myers TR, Kirchner HL, Kercsmar CM. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatr 2003; 143: 731-736.
31. Ralston ME, Euwema MS, Knecht KR, Ziolkowski TJ, Coakley TA, Cline SM. Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial. J Emerg Med 2005; 29: 29-35.
32. Haider D. Levalbuterol affords superior health and cost benefit over racemic albuterol in the emergency department. Resp Care 2001; 46: 1081.
33. Truitt T, Witko J, Halpern M. Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma. Chest 2003; 123: 128-135.
34. Nowak RM, Emerman CL, Schaefer K, Disantostefano RL, Vaickus L, Roach JM. Levalbuterol compared with racemic albuterol in the treatment of acute asthma: results of a pilot study. Am J Emerg Med 2004; 22: 29-36.
35. Berger We, Ames DE, Harrison D. A patient satisfaction survey comparing Levalbuterol with racemic salbutamol in children. Allergy Asthma Proc 2004; 25: 437-444.